Targeting HER2 in the treatment of non-small cell lung cancer

E-resources

Peer reviewed

Targeting HER2 in the treatment of non-small cell lung cancer

Mar, Nataliya; Vredenburgh, James J; Wasser, Jeffrey S

Lung cancer (Amsterdam, Netherlands), 03/2015, Volume: 87, Issue: 3

Journal Article

Highlights • Oncogenic driver mutations are treatment targets for molecular therapies in NSCLC. • HER2 positivity is well-studied in breast cancer, but poorly-defined in NSCLC. • Prognostic and predictive value of tissue-based assays in NSCLC need validation. • HER2 gene mutations may be associated with response to targeted agents in NSCLC. • All patients with HER2 positive NSCLC should be considered for targeted therapies.

Keep searching

Author

Mar, Nataliya | Vredenburgh, James J | Wasser, Jeffrey S

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme